Note 18 - Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash and cash equivalents	$ 2,108	$ 1,184	$ 2,108	$ 1,184	$ 12,645
Inventory, net	750		750		0
Prepaid expenses and other current assets	524		524		346
Property and equipment, net	12,343		12,343		12,641
Deferred offering costs	631		631		136
Licensed technology, net	2,243		2,243		2,243
Operating lease right-of-use assets, net	9,835		9,835		0
Goodwill	3,457		3,457		3,457
Other assets	214		214		124
Total consolidated assets of continuing operations	32,473		32,473		31,607
Research and development	2,704	655	4,558	990
Selling, general and administrative	3,720	1,023	7,500	2,065
Total operating expenses	6,424	1,678	12,058	3,055
Change in fair value of derivative liability	47	0	80	0
Interest income	11	3	35	7
Interest expense	(691)	0	(1,339)	0
Net other (expense) income	(633)	3	(1,224)	7
Net loss from operations before discontinued operations	(7,057)	(1,675)	(13,282)	(3,048)
Operating Segments [Member]
Cash and cash equivalents	2,108		2,108		12,645
Inventory, net	750		750		0
Prepaid expenses and other current assets	524		524		346
Property and equipment, net	12,343		12,343		12,641
Deferred offering costs	631		631		136
Licensed technology, net	2,243		2,243		2,243
Operating lease right-of-use assets, net	9,835		9,835		0
Goodwill	3,457		3,457		3,457
Restricted cash	368		368		0
Other assets	214		214		124
Total consolidated assets of continuing operations	32,473		32,473		31,592
Research and development	2,704	655	4,558	990
Selling, general and administrative	3,720	1,023	7,500	2,065
Total operating expenses	6,424	1,678	12,058	3,055
Change in fair value of derivative liability	47	0	80	0
Interest income	11	3	35	7
Interest expense	(691)	0	(1,339)	0
Net other (expense) income	(633)	3	(1,224)	7
Net loss from operations before discontinued operations	(7,057)	(1,675)	(13,282)	(3,048)
Biopharma [Member] | Operating Segments [Member]
Cash and cash equivalents	1,991		1,991		12,277
Inventory, net	750		750		0
Prepaid expenses and other current assets	78		78		156
Property and equipment, net	26		26		34
Deferred offering costs	631		631		136
Licensed technology, net	2,243		2,243		2,243
Operating lease right-of-use assets, net	0		0		0
Goodwill	0		0		0
Restricted cash	368		368		0
Other assets	130		130		124
Total consolidated assets of continuing operations	6,217		6,217		14,970
Research and development	1,544	655	2,401	990
Selling, general and administrative	1,431	1,023	3,485	2,065
Total operating expenses	2,975	1,678	5,886	3,055
Change in fair value of derivative liability	47	0	80	0
Interest income	11	3	35	7
Interest expense	(691)	0	(1,339)	0
Net other (expense) income	(633)	3	(1,224)	7
Net loss from operations before discontinued operations	(3,608)	(1,675)	(7,110)	(3,048)
CDMO [Member] | Operating Segments [Member]
Cash and cash equivalents	117		117		368
Inventory, net	0		0		0
Prepaid expenses and other current assets	446		446		190
Property and equipment, net	12,317		12,317		12,607
Deferred offering costs	0		0		0
Licensed technology, net	0		0		0
Operating lease right-of-use assets, net	9,835		9,835		0
Goodwill	3,457		3,457		3,457
Restricted cash	0		0		0
Other assets	84		84		0
Total consolidated assets of continuing operations	26,256		26,256		$ 16,622
Research and development	1,160	0	2,157	0
Selling, general and administrative	2,289	0	4,015	0
Total operating expenses	3,449	0	6,172	0
Change in fair value of derivative liability	0	0	0	0
Interest income	0	0	0	0
Interest expense	0	0	0	0
Net other (expense) income	0	0	0	0
Net loss from operations before discontinued operations	$ (3,449)	$ 0	$ (6,172)	$ 0